Navigation Links
Ranbaxy Receives Final Approval To Market Sumatriptan Succinate Tablets
Date:8/11/2009

PRINCETON, N.J., Aug. 11 /PRNewswire/ -- Ranbaxy Pharmaceuticals Inc. (RPI), a wholly owned subsidiary of Ranbaxy Laboratories Limited (RLL), announced today that RLL has received final approval from the U.S. Food and Drug Administration to manufacture and market Sumatriptan Succinate Tablets, 25 mg (base), and 50 mg (base). The Office of Generic Drugs, U.S. Food and Drug Administration, has determined the Ranbaxy formulations to be bioequivalent and have the same therapeutic effect as that of the reference listed drug Imitrex(R)* by GlaxoSmithKline. Total annual market sales for Sumatriptan Succinate 25 mg and 50 mg tablets were $379 million (IMS - MAT: June 2009) which is indicated for the acute treatment of migraine attacks with or without aura in adults.

"We are pleased to receive this final approval for Sumatriptan Succinate Tablets 25 mg and 50 mg in addition to the 100 mg that was previously approved. This FDA approval represents the sixth such authorization to commercialize product to be granted by the agency so far in 2009. This product will be launched immediately to all classes of trade and further expands our product portfolio of affordable generic product formulations, that will be of benefit to patients, healthcare professionals and the U.S. healthcare system," according to Bill Winter, Vice President, Trade Sales, North America.

Ranbaxy Pharmaceuticals Inc. (RPI) based in Jacksonville, Florida, is a wholly owned subsidiary of Ranbaxy Laboratories Limited (RLL), India's largest pharmaceutical company. RPI is engaged in the sale and distribution of generic and branded prescription products in the U.S. healthcare system.

Ranbaxy Laboratories Limited, headquartered in India, is an integrated, research based, international pharmaceutical company producing a wide range of quality, affordable generic medicines, trusted by healthcare professionals and patients across
'/>"/>

SOURCE Ranbaxy Pharmaceuticals Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related medicine news :

1. Ranbaxy Secures Final FDA Approval for Quinapril Hydrochloride + Hydrochlorothiazide Tablets
2. Press Statement Issued by Ranbaxy Laboratories Limited
3. Cipher Pharmaceuticals announces U.S. distribution and supply agreement with Ranbaxy for CIP-ISOTRETINOIN
4. Ranbaxy and Pfizer Settle Lipitor Litigation Worldwide
5. Ranbaxy to Bring in Daiichi Sankyo as Majority Partner; Strategic Combination Creates Innovator and Generic Pharma Powerhouse
6. Ranbaxy Receives Final Approval to Manufacture and Market Cetirizine Hydrochloride Oral Solution
7. Ranbaxy Gains Approval to Manufacture and Market Cefuroxime Axetil for Oral Suspension
8. Ranbaxy Receives Final Approval to Manufacture and Market Cetirizine Hydrochloride Tablets (OTC), 5mg and 10mg
9. Ranbaxy Receives Tentative Approval For Valsartan Tablets
10. Ranbaxy First to Gain Approval to Manufacture and Market Clarithromycin for Oral Suspension, USP
11. Ranbaxy Gains Approval to Manufacture and Market Carvedilol Tablets in the U.S. Market
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2014)... agents and light to kill tissue) appears to better ... by sun damage) at three months after treatment than ... , Author: Gayatri Patel, M.D., M.P.H., of the ... colleagues. , Background: AKs are rough, scaly ... fair complexions who have had lots of sun exposure. ...
(Date:8/27/2014)... 2014 BRIC Laparoscopes Market Outlook to ... key market data on the BRIC Laparoscopes market. The ... (in units) and average prices (in US dollars) within ... Flexible Tip Video Laparoscopes), Robotic Surgical Systems and Rigid ... advantages to the patient with laparoscopic surgery versus the ...
(Date:8/27/2014)... are known to play a key role in inflaming ... atherosclerosis. A new study at UCLA demonstrates that they ... disease that narrows the small blood vessels in the ... that a peptide mimicking part of the main protein ... help reduce the production of oxidized lipids in pulmonary ...
(Date:8/27/2014)... August 27, 2014 Dr. Stewart ... Center see multitudes of patients suffering from impaired vision. ... Cataract vision correction surgery . Recently, Dr. Shofner ... information during an eye exam and also online. To ... top five myths about glaucoma. , 1)    Myth: People with ...
(Date:8/27/2014)... The federal judge overseeing thousands of ... the deadline for plaintiffs to enroll in the U.S. ... by U.S. District Judge David Katz of the Northern ... DePuy ASR Settlement Program must do so by September ... Implant Products Liability Litigation – MDL 2197) , “Our ...
Breaking Medicine News(10 mins):Health News:Photodynamic therapy vs. cryotherapy for actinic keratoses 2Health News:Laparoscopes & Endoscopic Reprocessors Market in BRIC (Brazil, Russia, India & China) to 2020 Report Available at RnRMarketResearch.com 2Health News:Laparoscopes & Endoscopic Reprocessors Market in BRIC (Brazil, Russia, India & China) to 2020 Report Available at RnRMarketResearch.com 3Health News:Laparoscopes & Endoscopic Reprocessors Market in BRIC (Brazil, Russia, India & China) to 2020 Report Available at RnRMarketResearch.com 4Health News:Protein in 'good cholesterol' may be a key to treating pulmonary hypertension 2Health News:Renowned Eye Surgeon Dr. Stewart Shofner Debunks Top Five Myths About Glaucoma 2Health News:Renowned Eye Surgeon Dr. Stewart Shofner Debunks Top Five Myths About Glaucoma 3Health News:Renowned Eye Surgeon Dr. Stewart Shofner Debunks Top Five Myths About Glaucoma 4Health News:DePuy ASR Settlement Enrollment Deadline Extended Until September 30, 2014, Bernstein Liebhard LLP Reports 2Health News:DePuy ASR Settlement Enrollment Deadline Extended Until September 30, 2014, Bernstein Liebhard LLP Reports 3
... without obesity , TUESDAY, April 13 (HealthDay News) -- A ... insulin work together in the brain to control blood sugar ... , The findings also appear to suggest that diabetes and ... many physicians, think you develop diabetes that is solely secondary ...
... Prostate cancer will ... the African American community), making it the most common cancer among American men. Join the ... Prostate Cancer. , ... (PRWEB) April 13, 2010 -- Registration is now open for Little Red Door’s Unite 2 ...
... ... through Community , ... (PRWEB) April 13, 2010 -- Motivational Speaker/MS Advocate and Author Erin Morrow Still released ... Sclerosis. , , ,Published by iUniverse with a forward by Harold Moses Jr. ...
... have no social fear and appear open, friendly to ... -- Children with a rare condition called Williams ... racial prejudice, a new study shows. , The finding ... of racial stereotyping. , French and German researchers examined ...
... Finding underscores the need to treat Alzheimer,s patients ... 13 (HealthDay News) -- People with memory loss can ... a new study has found. , University of Iowa ... five patients with memory loss. The patients couldn,t remember ...
... Fifty-eight percent of Americans (96 percent of Republicans, 10 ... repealing the health care reform legislation that was signed ... to a new national survey conducted April 6 - ... Policy and Professionalism Research (CHPPR). Americans 18 ...
Cached Medicine News:Health News:Hormones Tied to Diabetes Might Also Influence Fertility 2Health News:Registration Now Open for Little Red Door's Unite 2 Fight Race Against Prostate Cancer Saturday, July 10, 2010 2Health News:Author Erin Morrow Still Releases "Fighting MS: Strength in Numbers" 2Health News:Author Erin Morrow Still Releases "Fighting MS: Strength in Numbers" 3Health News:Kids With Rare Condition Lack Racial Prejudice 2Health News:Even As Memory Fades, Emotions Linger 2Health News:Health care reform 'important' even to those who want new law repealed 2
(Date:8/27/2014)... By now, if you haven,t heard about the ALS Ice ... awareness campaign has brought this devastating disease to the forefront ... Million (and counting) for ALS. Every day, more and more ... as well. One such company, Acorn Stairlifts Inc., ... works with ALS sufferers and helps to provide solutions for ...
(Date:8/27/2014)... 27, 2014  Hill-Rom Holdings, Inc. (NYSE: ... presentation at the Morgan Stanley Global Healthcare Conference on ... You are invited to listen to the live discussion ... access it directly at http://cc.talkpoint.com/morg007/090814a_ac/?entity=26_7CLOGQP .  A recorded ... after conclusion of the live event and accessible at ...
(Date:8/27/2014)... 2014 North American lighting leader OSRAM SYLVANIA ... for the new OSRAM ITOS ® PHASER ® ... for microscopy, endoscopy and surgical head lamps that delivers the ... and lamp life. "We,re honored to be recognized ... innovative new technologies of the past year," said Andreas ...
Breaking Medicine Technology:Acorn Stairlifts Gives a Lift to the ALS Ice Bucket Challenge 2OSRAM ITOS PHASER 3000 Laser and LED Light Module Recognized With Prestigious R&D 100 Award 2OSRAM ITOS PHASER 3000 Laser and LED Light Module Recognized With Prestigious R&D 100 Award 3
Puros allografts is a family of bone products specially designed and processed to meet the demanding needs of spine surgeons. The grafts are processed using the proprietary Tutoplast process....
... Graftech cervical dowels are ... to graft expulsion and improve ... allows immediate red blood cell ... Grafton DBM gel into the ...
8 mm S Graftech cervical spacer....
Lorenz 2.0 mm titanium system for the midface provides an excellent alternative to lower profile systems in areas of the midface where greater fixation is needed....
Medicine Products: